X4 Pharmaceuticals has secured $60 million in equity financing, prompting leadership changes with new executives from CTI BioPharma. The funds will support commercialization of mavorixafor, their leading treatment for WHIM syndrome, while multiple prominent investors back the round, reflecting confidence in X4's pipeline.